Immuneering Releases Data Validating Atebimetinib As MAPK Backbone In Pancreatic & Thyroid Cancer
Immuneering (IMRX) released data supporting its lead drug, Atebimetinib, for pancreatic and thyroid cancer. The drug showed synergistic effects with chemotherapeutic agents in pancreatic cancer models and demonstrated anti-tumor activity in anaplastic thyroid cancer (ATC) models. IMRX is trading at $3.50, up 1.30%.


